Compounded vs branded medication
The difference is regulatory, not cosmetic, and it governs how your storefront is allowed to describe what you sell. Getting the language wrong is where brands attract attention.
Key takeaways
- Compounded preparations are not FDA-approved products in the way commercially manufactured drugs are.
- They are prepared by state-licensed pharmacies under federal and state law, and 503B facilities are FDA-registered and inspected.
- Storefront copy must describe this accurately rather than implying equivalence to a branded product.
- Comparative claims against branded products are where brands most often overreach.
- This is a marketing control as much as a clinical one, and it belongs in a pre-launch review.
The regulatory distinction
An FDA-approved branded medication has been through a specific approval process establishing safety and efficacy for defined indications, and is manufactured under conditions the FDA regulates.
A compounded preparation is prepared by a licensed pharmacy for a patient, under federal and state compounding law. 503A pharmacies compound against a prescription for an individually identified patient; 503B outsourcing facilities register with the FDA, comply with current good manufacturing practice requirements, and are subject to inspection.
Compounded preparations are lawful and widely used. They are simply not the same regulatory object as an approved product, and the distinction has to survive contact with your marketing copy.
What you can say
Accurate, specific description of what is being prepared and by whom.
- That the preparation is compounded by a state-licensed pharmacy.
- The active ingredients and strengths actually prescribed.
- That a licensed provider in the patient's state prescribes it after review.
- That compounding permits formulations and dose forms not commercially available.
- Factual statements about your own service: timelines, support, fulfillment.
Where brands overreach
Almost always in comparison. The temptation is to position a compounded preparation against a well-known branded product, because the branded name carries the demand.
Implying that a compounded preparation is the same as, equivalent to, or a generic version of an approved branded product is the specific pattern that attracts regulatory and platform attention. So is using branded trademarks in ways that suggest affiliation or approval.
The safest framing describes what you actually provide rather than what it resembles.
Availability changes, and copy has to keep up
Regulatory conditions affecting which compounds may be prepared, and in what circumstances, change over time. Copy written accurately eighteen months ago may not be accurate now.
That makes storefront language a maintenance item rather than a launch item. Someone should own re-reading it when conditions change, and it should not be the person who wrote it.
Why this is a commercial control
The consequence of getting this wrong is rarely a clinical incident. It is an ad account suspension, a platform policy strike, or a regulatory letter, any of which can stop acquisition overnight.
In a business where paid acquisition is the growth engine, accurate product description is not a compliance formality. It is what keeps the engine running.
Accurate description, and certification that survives review
PharmaBro routes to state-licensed 503A and 503B compounding partners and includes LegitScript certification at $0, which involves review of exactly this kind of patient-facing material.
Storefront copy is reviewed against FTC and ad-platform standards before launch, because in this category the copy is the risk surface.
Conclusion
Compounded medication is lawful, widely prescribed, and central to direct-to-consumer telehealth. It is also not the same regulatory object as an approved branded product.
Describe what you actually provide, avoid equivalence claims against branded products, and re-read the copy when conditions change. The clinical workflow is rarely what gets a brand into trouble; the comparison in the headline is.
Frequently asked questions
Is compounded medication FDA approved?
Compounded preparations are not FDA-approved products in the way commercially manufactured drugs are. They are prepared by state-licensed pharmacies under federal and state law, and 503B outsourcing facilities are additionally FDA-registered and subject to inspection.
Can I compare my compounded product to a branded drug?
Implying equivalence to, or generic status against, an approved branded product is the pattern most likely to attract regulatory and ad-platform attention. Describe the active ingredients, strengths and the prescribing and dispensing process instead.
Who reviews my storefront copy?
It should be someone other than the person who wrote it, reviewed against FTC and ad-platform standards before launch. Because regulatory conditions change, it should also be re-read periodically rather than treated as a one-time task.
Priya RaghunathanHead of Compliance Operations
Handles LegitScript, HIPAA posture, MSO structuring and state coverage. Writes the parts of this blog that operators wish someone had told them before they signed.